Skip to main content
Fig. 1 | Thrombosis Journal

Fig. 1

From: Edoxaban versus enoxaparin for the prevention of venous thromboembolism after total knee or hip arthroplasty: pooled analysis of coagulation biomarkers and primary efficacy and safety endpoints from two phase 3 trials

Fig. 1

Distribution of patients in the pooled data analyses. aThe safety analysis set included all enrolled patients who received study drug, had posttreatment safety data, and did not have significant GCP violations. bThe full analysis set included all patients receiving ≥1 dose of study drug and excluded patients with significant GCP violations or with inadequate venography. cMultiple answers were allowed; patients falling under multiple categories were counted once for each category. dThe per-protocol set included patients in the FAS and excluded patients with violations of inclusion or exclusion criteria, violation of rules for prohibited concomitant drugs/treatment, or <80% compliance with study drug. GCP = good clinical practice; FAS = full analysis set; THA = total hip arthroplasty; TKA = total knee arthroplasty

Back to article page

Thrombosis Journal

ISSN: 1477-9560

Contact us